BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2016 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced its participation in two upcoming investor conferences:
- Canaccord Genuity Rare Disease, BioPharma 1x1 Day
Tuesday, February 2, 2016
Omni Berkshire Place Hotel, New York, NY
- SunTrust Robinson Humphrey 2016 Orphan Drug Day
Tuesday, February 23, 2016
JW Marriott Essex House, New York, NY
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biopharmaceutical company developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, with an initial focus on immunotherapy and oncology. Atara Bio’s programs include T-cell product candidates and molecularly targeted product candidates. The T-cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434. These product candidates target activin and myostatin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.
INVESTOR & MEDIA CONTACT: Investors: Steve Klass 212-213-0006 x331 [email protected] Media: Justin Jackson 212-213-0006 x327 [email protected]
